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ABSTRACT  
The transfer of genomic information into the primary RNA sequence can be altered by RNA editing. 
We have previously shown that genomic variants can be RNA-edited to wild-type. The presence of 
distinct ‘edited’ IDS mRNA-transcripts  ex vivo evidenced the correction of a nonsense and frameshift 
variant, respectively, in three unrelated Hunter syndrome patients. This phenomenon was confirmed 
in various patient samples by a variety of techniques, and quantified by single nucleotide primer 
extension. Western blotting also confirmed the presence of IDS protein similar in size to the wild-
type. Since preliminary experimental evidence suggested that the ‘corrected’ IDS proteins produced 
by the patients were similar in molecular weight and net charge to their wild-type counterparts, an in 
vitro system employing different cell types was established to recapitulate the site-specific editing of 
IDS RNA (U–to-C conversion and U deletion), and to confirm the findings previously observed ex 
vivo in the three patients. In addition, confocal microscopy and flow cytometry  analyses 
demonstrated the expression and lysosomal localization in HEK293-cells of GFP-labeled-proteins 
translated from edited IDS mRNAs. Confocal high-content analysis of the two patients’ cells 
expressing wild-type or mutated IDS confirmed lysosomal localization and showed no accumulation 
in the Golgi or early endosomes. 
 
Key words: RNA editing conversion and deletion; mutation correction; edited IDS-transcripts to 
wild-type; confocal microscopy; imaging flow cytometry; western blot; SDS-PAGE; single 
nucleotide primer extension; expression vectors  
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Introduction 
The transfer of genomic information into the primary RNA sequence can be altered by RNA editing 
at either the transcriptional or post-transcriptional level. Initially, this mechanism was thought to be 
quite rare in human cells [Bass, 2002].  However, over the past few years, multiple studies, both 
computational and experimental, have shown that RNA editing contributes extensively to the 
complexity evident at both the transcriptome and proteome levels [Li et al., 2011; Chen and 
Bundschuh,  2012; Kleinman et al.,  2012; Peng et al.,  2012; Zhu et al.,  2012; Chen, 2013; Rieder 
et al.,  2013; Bazak et al., 2014; Daniel et al., 2014; Li and Maso 2014; Savva and Reenan 2014; Xu 
and Zhang 2014]. In facilitating the genome-wide comparison of DNA and RNA sequences, the 
development of next generation sequencing (NGS) technology has served to greatly speed up studies 
of RNA editing [Piskol et al., 2013; Chen et al., 2014]. RNA editing is now recognized as a key level 
of regulation that is responsible for modulating a variety of cellular functions including protein 
activity, alternative mRNA splicing, and the alteration of miRNA target sites [Kim et al., 2016]. It 
should however be appreciated that the amount of RNA editing observed actually represents a 
population average of cells exhibiting a broad spectrum of rates of editing leading to the emergence 
of subsets of cells with differing informational content at the RNA level [Harjanto et al., 2016]. 
A number of different forms of mRNA editing have been reported in the human genome (dbRES) 
[http://bioinfo.au.tsinghua.edu.cn/dbRES] and several mechanisms have been described, ranging 
from co-, post- or co-post-transcriptional nucleotide modification, to nucleotide insertion or deletion 
[Bazak et al., 2014]. In human, RNA editing was first described as a C-to-U conversion in 
apolipoprotein B (APOB) primary transcripts by hydrolytic deamination giving rise to major 
alternative isoforms in the intestine (APOB48) and liver (APOB100), respectively [Wedekind et al., 
2003; Navaratnam  and Sarwar, 2006]. RNA editing is also known to modify RNAs in such a way as 
to introduce amino acid substitutions causing human genetic disease [Slotkin and Nishikura, 2013]. 
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Cytidine (C) to uridine (U) and adenosine (A) to inosine (I) transitions are the best characterized 
mammalian mRNA editing mechanisms reported to date. Generally, in mammalian cells, cytidine to 
uridine (C to U) and A to I changes have been observed in both coding and noncoding sequences, 
including microRNAs; dysregulation can lead to pathogenesis [Gott, 2011; Maas et al., 2006; 
Grohmann et al., 2010; Ramaswami and Li, 2016]. 
Far less common is the U-to-C editing of mRNA (and tRNA) that has been observed in both the 
nucleus and mitochondria of mammals [Villegas et al., 2002; Niavarani et al., 2015]; at present, the 
underlying enzymatic processes have not been elucidated.  In human, the transcript of the Wilms' 
tumor susceptibility gene, WT1, undergoes RNA editing by U to C conversion, thereby affecting the 
transcriptional repression function of the WTl protein [Sharma et al., 1994; Mrowka and Schedl, 
2000]. U-to-C RNA editing has also been identified in long primary mi-RNAs (pri-miRNAs) [Blow 
et al., 2006; Griffiths-Jones et al., 2008].    
An additional mechanism, U deletion mRNA editing, was first reported as a posttranscriptional 
modification of the RNA sequence in kinetoplastids, a group of flagellate protozoa [Estévez and  
Simpson, 1999; Osato et al., 2009]. However, evidence has emerged for the fairly frequent occurrence 
of U insertion editing in the human genome, where it represents a mechanism capable of creating 
different protein isoforms [Zougman et al., 2008]. Although the site specificity and basic mechanism 
of U insertion editing have not been experimentally demonstrated in all cases [Chen and Bundschuh, 
2012], it has been shown in the trypanosomatids that specificity is determined by complementary 
guide RNAs (gRNAs) which act in trans to guide the RNA editing core complex (RECC, the 20S 
editosome) to the site of U-insertion or U-deletion by base pairing [Cruz-Reyes et al., 2001; 
Aphasizhev and Aphasizheva, 2011].  It was recently reported in trypanosomatids that this type of 
editing serves to correct frameshifts, introduce translation punctuation (start and stop) signals, and 
can even add hundreds of uridines to create novel protein-coding sequences [Aphasizheva and 
Aphasizhev, 2016].  
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More recently, a strategy based upon artificial RNA-guided editing machinery has been developed to 
re-program genetic information at the RNA level and it has been shown that such a strategy is capable 
of repairing disease-relevant genes, such as CFTR, not only in mammalian cell culture but also in 
simple organisms [Reautschnig et al., 2016]. Previously, we reported that human IDS gene variants 
affecting function were RNA-edited ex vivo by an as yet unidentified mechanism, which led to the 
expression of variable amounts of non-mutated (i.e. wild-type) IDS transcripts in a tissue-dependent 
fashion [Lualdi et al., 2010]. These mutational events were observed in three male patients affected 
by Hunter syndrome or mucopolysaccharidosis type II (MPS II, OMIM# 309900), a rare X-linked 
recessive lysosomal disorder caused by the deficiency of iduronate-2-sulfatase (IDS; EC 3.1.6.13) 
resulting from hemizygous genomic variants in the IDS gene (OMIM #309900; GenBank Accession 
No. NG_011900.1). Nearly 60% of the >550 different IDS variants reported to date (see the Human 
Gene Mutation Database) [http://www.hgmd.cf.ac.uk/ac/index.php; Stenson et al., 2017], are 
sequence variants with the potential to impact RNA processing in some way. This is how, during the 
course of IDS RNA analysis, we observed, in 3 unrelated male (hemizygous) Hunter syndrome 
patients, evidence of ex vivo correction (at the RNA level) of their gene lesions characterized at the 
DNA level [Lualdi et al., 2010]. The presence of two distinct “edited” IDS mRNA-transcripts (U-to-
C and delU, correcting a nonsense variant and a frameshift variant, respectively) in different patients, 
was confirmed in various tissues and cell lines from the patients by several different techniques and 
quantified by single nucleotide primer extension (SNuPE). Western blotting analysis confirmed the 
presence of IDS precursor protein similar in size to the wild-type. We were left with the intriguing 
possibility that an mRNA correction mechanism akin to RNA editing had been activated in our 
patients. Here, we have confirmed by SDS-PAGE Western blot that the ‘corrected’ IDS-proteins, 
synthesized from edited IDS mRNAs produced by the patients, are similar in terms of molecular 
weight and net charge to their wild-type counterparts. Prompted by this experimental evidence, an in 
vitro system, employing different cell types, was used to recapitulate the site-specific editing of RNA 
(both U–to-C conversion and U deletion), and to confirm the findings previously observed ex vivo in 
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the three patients. In addition, confocal microscopy, flow cytometry and imaging flow cytometry 
analyses provided evidence for both the expression and lysosomal localization in HEK293 cells of 
GFP-labeled proteins translated from edited IDS mRNAs. Confocal high-content analysis of the two 
patients’ cells expressing wild-type or mutated IDS confirmed lysosomal localization and showed no 
accumulation in the Golgi or early endosomes. 
 
MATERIALS AND METHODS 
Patient and control samples 
Fibroblast and lymphoblast cell lines were grown from the two unrelated Italian MPS II patients (pts) 
respectively hemizygous for the IDS genomic variants, c.22C>T and c.10insT (by contrast, at the 
RNA level, the presence of edited IDS mRNA transcripts c.22U>C and c.10delU, respectively, was 
evident). The c.22C>T and c.10insT variants, both of which are located in exon 1, predicted the 
truncating variants p.R8X and p.P4SfsX43, respectively. Fibroblast and lymphoblast cell line samples 
from a wild-type male individual were used as negative controls. Fibroblasts harbouring the IDS 
mutant p.W12X (c.35G>A), which proved not to be prone to RNA editing, were also included in the 
experiments. 
The patient’s samples were obtained from the “Cell Line and DNA Biobank from patients affected 
by Genetic Diseases” [Filocamo et al., 2014].  Owing to the paucity of Biobank samples, only one of 
two patients known to harbour the c.22C>T (R8X) was studied in the present work. 
Ethical aspects. Following ethical guidelines, all samples for analysis and storage were obtained with 
the patients’ (and/or the legal guardian’s) written informed consent. Consent was sought using a form 
approved by the local Ethics Committee. 
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Variant nomenclature. According to current variant nomenclature recommendations (Human 
Genome Variation Society) [http://varnomen.hgvs.org/; den Dunnen et al., 2016], the above 
mentioned variants, p.R8X, p.P4SfsX43 and p.W12X, should be designated p.R8*, p.P4Sfs*43 and 
p.W12*, respectively. However, as the present study represents a continuation of that published 
previously [Lualdi et al., 2010], the former variant designation is used throughout the text in order to 
maintain continuity.  
 
Cell culture 
In-house established human fibroblasts and the commercially available human cell lines, HeLa and 
HEK293, were cultured according to standard procedures and maintained in RPMI medium 
(EuroClone, Gibco, Paisley, UK) containing 15% FCS and penicillin/streptomycin, in a humidified 
atmosphere containing 5% CO2 at 37°C. The human fibroblasts were tested for mycoplasma 
contamination before use. 
Biochemical studies on IDS protein from patient cell lines 
Cells collected for all electrophoresis experiments were counted, washed in TBS and solubilised in 
Laemmli sample buffer for SDS-reduced-PAGE and 2D-PAGE, or in Tris/Boric acid/ EDTA buffer 
for Native-PAGE. Sample concentrations were determined by means of a bicinchoninic acid protein 
assay. 
Native-PAGE. Samples (50 g) were solubilised in 90 mM Tris, 80 mM Boric acid and EDTA buffer 
at pH 8.6 containing phosphatase and protease inhibitor cocktail and loaded onto a gel (T% 8–16) 
with the same buffer in a Protean II XI system (Bio-Rad, Hercules, CA, USA). 
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SDS-reduced-PAGE. Samples (50 g) were solubilised in Laemmli sample buffer containing 50 mM 
DTE and phosphatase and protease inhibitor cocktail. Samples were then boiled for 10 min and 
separated in a SDS-PAGE (T% 8–16) with a Protean II XI system (Bio-Rad).   
2D-PAGE. The solubilised samples (200 g) were cleaned and precipitated using an ice-cool mixture 
of tri-n-butyl-phosphate:acetone:methanol with ratio of 1:12:1 (TBPAM) as previously reported 
[Bruschi et al., 2005] with some modifications. Briefly, this mixture was added to each sample to 
reach a final acetone concentration of 80% (v/v) and incubated for 90 min at 4°C. The precipitate was 
pelleted by centrifugation at 2800 x g for 20 min at 4°C. Supernatant was discarded and the pellet 
was washed with 1 ml tetrahydrofuran (THF) precooled on ice. After centrifugation at 10000 × g for 
10 min at 4°C, the pellet was air dried, dissolved in the sample focusing solution (7M urea, 2M 
thiourea, 4% (w/v) CHAPS, and 50 mM DTE) and loaded onto home-made non-linear pH 3–10 soft-
IPG strips (18 cm long, 3 mm wide, 0.5 mm thick) [Bruschi et al., 2003]. Strip re-swelling was carried 
out overnight at room temperature in the focusing solution, 7M urea, 2M thiourea, 2% (w/v) CHAPS, 
15 mM DTE, and 0.6% (v/v) carrier ampholyte cocktail, containing 40% of the pH 3.5–10 and 60% 
of the pH 4–8 intervals. 
The proteins were focused at ≤ 50 mA per strip at 20°C, using a progressively increasing voltage for 
a total of 90000 Vh. An equilibration step was performed for 30 min in the equilibration buffer 
containing 6 M Urea, 50 mM Tris-HCl pH 8.8, 2% (w/v) SDS, 30% (v/v) glycerol, and a trace of 
bromophenol blue. In the second dimension, the proteins were separated on an SDS-PAGE gel (T% 
8–16) with a Protean II XI system (Bio-Rad). 
Western Blotting. After the electrophoretic separation, the samples were transferred onto  
nitrocellulose membrane (Protean BA, Schleicher & Schuell, Dassel, Germany) with a Novablot 
semi-dry system, 3% w/v BSA saturated in TBS and incubated separately with 1:1000 anti-IDS (Santa 
Cruz Biotechnologies, CA, USA), anti-IDS (Abnova, Taiwan, Taipei), anti--tubulin (Sigma, Saint-
Louis, USA) in 3% w/v BSA in TBS-Tween 0.05% v/v (TBS-T). Membranes were then rinsed in 
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TBS-T and incubated with secondary antibody. Chemiluminescence was used for immunodetection. 
Images were digitalized by mean of VersaDoc 4000 (Bio-Rad) and analyzed with QuantityOne 
software (Bio-Rad). 
Immunoprecipitation. Immunoprecipitation by anti-IDS antibody (Abnova, Taiwan, Taipei) was 
performed with 1 mg protein from whole cell lysates. After pre-cleaning by protein A Sepharose, the 
samples were incubated with anti-IDS antibody overnight at 4°C with gentle rotation. The protein A-
Sepharose beads were then washed extensively with washing buffer and eluted with 2D-PAGE 
focusing solution. The bound proteins eluted from the beads were separated on 2D-PAGE and the 
gels were subjected to silver staining.  
Construction of full-length IDS cDNA vector for in vitro expression 
RT-PCR products of full-length IDS cDNAs, obtained using primers located in the 5’UTR and 3’UTR 
respectively [Lualdi et al., 2010], were cloned into the plasmid vector pcDNA3.1/V5-His–TOPO, 
containing the CMV promoter and T7 promoter (see map) 
[http://tools.invitrogen.com/content/sfs/manuals/pcdna3.1topota_man.pdf], to generate IDS cDNA 
constructs as follows: (i) mutants p.R8X (c.22C>T) and  p.P4SfsX43 (c.10insT) both of which proved 
to be RNA editing-prone; (ii) wild-type (negative control); (iii) mutant p.W12X (c.35G>A) (positive 
control) which shares with the two variants under investigation the characteristics of (a) affecting the 
same IDS gene region (signal peptide), and (b) introducing a premature termination codon, but which 
differs from these aforementioned variants in terms of not being RNA editing-prone. 
The four different constructs were transformed into competent E. coli cells using the One Shot TOP10 
Chemical Transformation Kit (Invitrogen). Clones were isolated by QIAprep Kit (Qiagen). The 
presence of the insert in the construct was confirmed by restriction enzyme digestion, whilst the 
sequences of all constructs were checked for potential additional variants by DNA sequence analysis. 
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Transfection of the full-length IDS cDNA constructs and characterization of transcripts by 
Single Nucleotide Primer Extension (SNuPE) analysis 
Eight g of each vector were transfected by Lipofectamine® Reagent (Invitrogen), without antibiotics 
according to the manufacturer’s recommended instructions, into the different cell types (>95% 
confluent): viz. fibroblast cell lines from both patients (p.R8X and p.P4fsX43) and HEK293 and HeLa 
cell lines (normal control). After 48 h/72 h, the cells were trypsinized and washed in PBS. Total 
cytoplasmic RNA was extracted using RNeasy Mini and Plus Micro kit (Qiagen) to prevent genomic 
DNA contamination, and reverse transcribed using the SuperScript® VILO™ cDNA Synthesis Kit 
(Invitrogen). To amplify the fragment containing all three variants under investigation, [c.22C>T 
(p.R8X)], [c.10insT (p.P4 SfsX43)] and [c.35G>A (p.W12X)], RT-PCR was performed with a pair of 
primers, the forward primer (5’-GGAGACCCAAGCTGGCTAGT-3’) being complementary to the 
T7 promoter site (upstream of the IDS 5’UTR) and the reverse primer (5’-
GGTCACATAGCCATTCTCCTTG-3’) being located within exon 3. The use of the T7 primer 
allowed us to selectively amplify, and hence distinguish the exogenous IDS transcripts from the 
endogenous IDS transcripts. The amplified products were analyzed by electrophoresis on 1.5% 
agarose gels followed by staining with Atlas ClearSight DNA Stain (Bioatlas). 
To quantify the relative amounts of edited/non-edited transcripts, SNuPE analysis of RT-PCR 
products was performed using specific primers for [c.22C>T (p.R8X)], [c.10insT (p.P4SfsX43)] and 
[c.35G>A (p.W12X)] according to the previously described procedure [Lualdi et al., 2010]. 
Construction of pAcGFP1-N vector containing full-length IDS cDNAs 
RT-PCR products of full-length IDS cDNA were then cloned into the plasmid vector pAcGFP1-N In-
Fusion Ready Vector (see map) 
[http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=17882] according to the 
manufacturer’s  instructions, using the forward 5’-
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AAGGCCTCTGTCGACGCCACCTGCTGCAGCCTGTCC-3’ and the reverse 5’-
AGAATTCGCAAGCTTAGGCATCAACAACTGGAAAAG-3’ primers, respectively. The IDS 
cDNA sequence was added in-frame to that of the AcGFP1 coding sequence to generate an in-frame 
fusion protein to the N-terminus of AcGFP1. The resulting constructs contained: (i) normal WT-IDS 
(negative control); (ii) R8X(c.22C>T)-IDS mutant prone to the RNA editing-like mechanism, and 
(iii) the W12X(c.35G>A)-IDS mutant not prone to the RNA editing-like mechanism. The pAcGFP1-
N vector harbouring IDS(p.P4Sfs) was excluded from the analysis because of its low protein 
expression as revealed by Western blot analysis.   
The four different constructs were then transformed into Stellar competent E. coli cells by means of 
the In-Fusion HD Cloning Kit (Clontech). Clones were isolated by QIAprep Kit (Qiagen). All 
constructs were checked for accidentally-introduced variants by enzyme restriction digestion and 
sequencing analysis. 
Confocal microscopy 
For live-cell imaging experiments, HEK293 cells were cultured on glass coverslips. When 95% 
confluence was reached, cells were transiently transfected with 1.5 g of either p-IDS(WT)-AcGFP1-
N, p-IDS(R8X)-AcGFP1-N or p-IDS(W12X)-AcGFP1-N plasmids using Lipofectamine® Reagent 
(Invitrogen), as described above. After 48 h transfection, the nuclei of HEK293 cells were stained by 
adding 1 µg/ml Hoechst 33342 dye (Enzo Life Sciences) to the culture medium. After 15 mins, the 
medium was removed, cells were washed with phosphate-buffered saline (PBS) and then incubated 
for 30 mins in PBS containing 100 nM LysoTracker Deep Red (Invitrogen). LysoTracker is a weakly 
basic fluorescent dye that stains acidic organelles, in particular lysosomes. Cells were maintained for 
30 mins at 37°C in a 5% CO2-containing incubator.  For confocal microscopy, the coverslip with 
stained cells was removed and placed, inverted, on a microscope slide. The borders were sealed to 
avoid evaporation of the thin liquid film sandwiched between the two glasses. For confocal 
microscopy, the cells were placed on the stage of a laser-scanning microscope (Leica SP8) under a 
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40X, oil immersion objective (N.A. 1.3). GFP was laser excited at 488 nm and the emission 
wavelength was collected between 495 and 590 nm. LysoTracker Deep Red was excited at 633 nm 
and the emission wavelength captured between 640 and 750 nm. Hoechst 33342 was excited at 405 
nm and the emission captured between 410 and 460 nm. Excitation of the different fluorochromes 
was performed sequentially. After acquisition of each set of fluorescent images, a differential 
interference contrast (DIC) image was obtained to make clear the cells’ position and morphology. 
Fluorescent image reconstruction and merging were performed using ImageJ software. 
 
Transfection with vector p-IDS-AcGFP1-N in the HEK293 cell line for flow cytometric and 
imaging flow cytometry analyses 
HEK293 cells, cultured on T25 flasks, were transiently transfected (>95% confluent) with 3.75 g p-
IDS(WT)-AcGFP1-N, p-IDS(R8X)-AcGFP1-N or p-IDS(W12X)-AcGFP1-N plasmids using 
Lipofectamine®Reagent (Invitrogen) without antibiotics according to the manufacturer’s 
instructions. After 48 h, the cells were trypsinized and washed in PBS. HEK293 cells were stained 
with 100 nM solution of LysoTracker Deep Red (Invitrogen) in PBS for 30 mins at 37°C in 5% CO2 
for Imaging flow Cytometry analysis. 
Flow cytometric analysis. 
All flow cytometric samples were acquired on a four laser Gallios (Beckman Coulter) while, after 
acquisition, compensation and data analysis were performed with Kaluza software (Beckman 
Coulter). HEK293 cells were evaluated on the basis of their level of GFP protein expression. 
Imaging flow cytometry (IFC) analysis. 
Cells were analyzed in the ImageStreamX Mark II imaging flow cytometer (Amnis Corporation, 
Seattle, WA) equipped with a MultiMag system. Data were acquired using INSPIRE acquisition 
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software (Amnis, Merck). 5000 events were recorded using a 20x objective in order to perform 
quantitative analyses of samples whilst 1000 events where collected with both 40x and 60x objective 
lenses to obtain an improved view of the analyzed co-localization of GFP and LysoTracker. 
Upon focus, cells were initially identified from the bright-field images by using an algorithm 
recommended by the manufacturer, the Gradient RMS (root mean square) feature. Since HEK293 is 
an adherent cell line that tends to form aggregates even when resuspended strongly, we took 
advantage of two other features of INSPIRE software, Area and Aspect Ratio (the smallest width 
divided by the longest; for single cells, this ratio should usually be 0.8-1), which allowed us to 
specifically focus our attention on single cell events. Thanks to these features, we were able to 
optimize sample collection by recording only those events corresponding to perfectly in-focus single 
cells. To perform this analysis, four ImageStream channels were used: channel 1 for the bright-field, 
channel 2 for GFP (excited by a 488nm laser), channel 5 for LysoTracker (excited by a 642nm laser). 
Data were then analyzed using IDEAS 6.0.3 software (Amnis, Merck). Compensation was set on the 
basis of a matrix calculated by IDEAS software using single-stained samples (GFP and LysoTracker 
respectively) obtained with the same laser setting used for acquisition but with the bright-field light 
switched off, as suggested by the manufacturer 
Confocal high-content imaging and analysis of IDS protein expression and subcellular 
localization. Fibroblasts from healthy or Hunter syndrome individuals were plated on clear-bottom 
black 96 well/plate suitable for high-content imaging. After 72 hours, cells were fixed with neutral-
buffered formalin and permeabilized with Triton X-100 (0.2%). Fixed cells were then incubated with 
anti-IDS (R&D), anti-LAMP1 (Santa-Cruz), anti-giantin (Covance) and anti-EEA1 (GeneTex) 
antibodies at a concentration of 0.25 μg/ml for 2 h at 37°C. After washing with PBS, cells were 
incubated with AlexaFluor 647 anti-mouse IgG2b (for IDS), AlexaFluor 488 anti-mouse IgG1 (for 
LAMP-1) and  AlexaFluor 546 anti-rabbit IgG (for giantin or EEA1) secondary antibodies (Life 
Technologies).  
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Confocal high-content imaging and data analysis of cells were performed using an Opera Phenix 
(PerkinElmer) equipped with two cameras and synchrony optics that allow simultaneous acquisition 
(without crosstalk) of two fluorophores. Cells were imaged using a 40X water immersion objective 
(N.A. 1.1). AlexaFluor 488 signals were laser excited at 488 nm and the emission wavelength were 
collected between 500 and 550 nm. AlexaFluor 546 was excited at 561 nm and the emission 
wavelength captured between 570 and 630 nm. Hoechst 33342 was excited at 405 nm and the 
emission wavelength captured between 435 and 480 nm.  
Data analysis of co-localization was performed on approximately 100 cells per condition, by using 
the Harmony software (ver 4.5) of the Opera Phenix high-content system. 
RESULTS 
Biochemical studies on IDS protein from patient cell lines. 
Western blots of SDS-reduced-PAGE and native-PAGE gels revealed a unique protein product, with 
a molecular weight comparable to that of IDS (MW=61.9kDa) in both patient samples (p.R8X and 
p.P4SfsX43); a reduced protein concentration was noted exclusively in the patient harboring  p.P4Sfs, 
as compared to the control  (Figure 1). 
To verify the absence of any difference in molecular weight and/or net charge modification of IDS 
protein from the patients as compared to the control, a western blot of two-dimensional gel 
electrophoresis was performed. Unfortunately, the IDS antibodies employed did not detect any 
protein spots (data not shown). To resolve this problem, immunoprecipitation of the protein was 
performed by anti-IDS; as shown in Figure 2, at the appropriate molecular weight and isoelectric 
point of IDS protein (pI=5.45), a family of three protein spots was noted which exhibited similar 
expression to the IDS profile in western blot experiments.  
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Correction of the IDS gene lesions by editing at the RNA level in a transient expression study. 
In an attempt to reproduce in vitro the previously documented RNA editing-like mechanisms 
[conversion of U to C in the case of c.22C>T (p.R8X) and a U deletion in the case of c.10insT 
(p.P4SfsX43)], we set up an expression system in different cellular models including human 
fibroblasts, HeLa and HEK293 cell lines. Specifically, the wild-type IDS cDNA and the mutant IDS 
cDNAs [c.22C>T (p.R8X), c.10insT (p.P4SfsX43) and c.35G>A (p.W12X)] were inserted into the 
plasmid vector pcDNA3.1/V5-His–TOPO, containing the CMV promoter and T7 promoter, and then 
introduced by lipid-mediated transfection into: (i) fibroblasts from the two patients exhibiting the 
RNA editing-like mechanism(s), conversion and deletion, respectively; (ii) normal fibroblasts; and 
(iii) commercially available human cell lines viz. HeLa and HEK293. To quantify the amount of 
nucleotide correction (U>C and delU, respectively), SNuPE of RT-PCR products was performed with 
specific primers as previously described [Lualdi et al., 2010]. 
The SNuPE results showed that the plasmid constructs harbouring p.R8X and p.P4SfsX43 yielded 
the expected transcripts (i.e. both mutated and corrected to wild-type) in cellula, not only when they 
were transfected into Hunter syndrome patient fibroblasts (which of course display the RNA editing-
like phenomenon) but also when they were transfected into healthy donor fibroblasts and 
commercially available cell lines viz. HeLa and HEK293. As indicated in Table 1, the extent of 
nucleotide correction ranged from 17% to 53% for the U deletion [c.10insT (p.P4SfsX43)], and from 
0% to 63% for the conversion of U to C [c.22C>T (p.R8X)], depending upon the type of transfected 
cell. In agreement with the ex vivo results observed in the patients in the previous study [Lualdi et al., 
2010], no correction occurred in cellula with c.35G>A (p.W12X). Consistent with this finding, 
capillary electrophoresis revealed a bimodal pattern indicating the presence of two distinct 
populations of IDS mRNA transcripts (Figures 3 A-B) when the mutant constructs, c.10insT 
(p.P4SfsX43) and c.22C>T (p.R8X), were transfected into the (same) patient’s fibroblasts [i.e. 
c.10insT (p.P4SfsX43) into patient fibroblasts harbouring c.22C>T (p.R8X) and vice versa] or into a 
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control. By contrast, Figure 3C depicts a unimodal capillary electrophoretic pattern when the mutant 
c.35G>A (p.W12X) construct (positive control) was transfected into all cell types, a pattern that 
indicates the presence of 100% IDS mutated (i.e. unedited) transcripts. The results obtained suggest 
that the proportion of edited IDS mRNA transcripts varied depending upon the nature of the variant 
involved and the cell type in which the constructs were expressed.  
Confocal microscopy analysis: evidence of IDS-GFP expression and IDS-GFP lysosomal 
localization in HEK293 cells transfected with the pAcGFP1-N vector harbouring IDS(WT), 
IDS(R8X) and IDS(W12X). 
Evidence of expression. HEK293 cells transfected with both p-IDS(WT)-AcGFP1-N and p-
IDS(R8X)-AcGFP1-N vectors showed abundant green GFP staining, indicating the high level 
expression of chimeric protein which was distributed within the cytoplasm of the cell with an evident 
colocalisation in the lysosomes  (Figure 4 A-B). By contrast, expression levels of the IDS(W12X)-
GFP fusion protein, bearing a stop codon that is predicted to lead to premature termination of 
translation (but empirically shown not to be prone to mRNA correction) were, as expected, scarcely 
visible (Figure 4 C). 
Evidence of lysosomal localization. LysoTracker stained acidic cellular compartments in all cells. 
Overlaying red and green fluorescence into a merged image revealed those regions where both 
IDS(WT)-GFP and IDS(R8X)-GFP co-localized with Lysotracker (yellow staining indicated by 
arrows), suggesting IDS-GFP lysosomal localization, albeit only partial (Figure 4, fourth column, A 
and B). 
Flow cytometry (FC) analysis: quantification of IDS-GFP expression in HEK293 cells 
transfected with the pAcGFP1-N vector carrying IDS(WT), IDS(R8X) and IDS(W12X). 
As an adherent cell line, HEK293 cells tend to stick together. For this reason, and in order to avoid 
doublets or triplets that could alter the proportions of positive GFP events, Side Scatter (SSC) peak 
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width was plotted against SSC peak height, allowing clear discrimination between single cells and 
doublets (Figure 5 A). These doublets were then gated out and single cells were analysed for their 
GFP expression. As shown in Figure 5 B, the samples expressing IDS(WT)-GFP and IDS(R8X)-GFP 
fusion proteins showed comparable proportions of positive events with similar mean fluorescence 
intensity (MFI). By contrast, the samples expressing IDS(W12X)-GFP  showed only slight positivity, 
being present in only 16% of the cell population, with a noticeably lower MFI. Flow cytometry 
quantification analysis therefore confirmed that the amount of corrected-fusion-IDS protein was 
comparable to that of the wild-type IDS protein. 
Imaging Flow Cytometry (IFC) analysis: evidence of lysosomal localization and quantification 
of IDS-GFP expression in HEK293 transfected cells with pAcGFP1-N vector harbouring 
IDS(WT) and IDS(R8X). 
In order to perform a semi-quantitative analysis of the samples from transfected cells, we acquired 
5000 cellular events using a 20x objective. We further optimized the analysis by focusing exclusively 
on events that corresponded to perfectly in-focus single cells (Figure 6 A-B). Data obtained for both 
IDS(WT)-GFP and IDS(R8X)-GFP fusion protein expression in HEK293 showed comparable 
percentages (Figure 6 C), thereby confirming what had already been observed by flow cytometry. In 
contrast to classical cytometry, through which we could only establish if two markers of interest 
(LysoTracker and GFP) were coexpressed in the same cell, IFC also allowed us to determine whether 
or not LysoTracker and GFP co-localized. To identify the cell sub-population bearing the co-
localization of interest, we applied a feature called “bright detail similarity” to a custom mask (Figure 
6 D). Through the algorithm obtained, we were able to define a cluster of the best images of those 
events exhibiting high expression of both markers in the same position of the cell surface at the same 
time. This analytical strategy was also applied to cellular events acquired with both 40x and 60x 
objectives, in order to perform a qualitative analysis leading to good lysosomal localization pictures 
of both IDS(WT)-GFP and IDS(R8X)-GFP fusion proteins expressed in vitro (Figure 6 E-F). Overall, 
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analysis of the data allowed us to confirm that the IDS protein produced using the edited mRNA as 
template was comparable to the wild-type IDS protein both in terms of its amount and its lysosomal 
localization. 
Confocal high-content screening system: imaging and analysis of IDS protein expression and 
subcellular localization in patient cell lines. High-content imaging analysis was performed on 
fibroblasts from control and Hunter syndrome individuals using the Opera Phenix system 
(PerkinElmer). This analysis revealed that in control fibroblasts wild-type IDS protein is expressed 
and co-localizes with LAMP-1, a lysosomal marker. Co-localization of the two signals was higher 
than 90% (Figure 7A). By contrast, the expression of W12X-IDS in fibroblasts from a Hunter 
syndrome patient was extremely low (an ~100-fold decrease as compared to the expression of wild-
type IDS) with no co-localization with the lysosome marker LAMP-1 (Figure 7B). However, 
fibroblasts from Hunter syndrome patients bearing either the p.R8X (Figure 7C) or p.P4Sfs (Figure 
7D) mutation display very high levels of expression of the edited-to-wild-type mutant protein (a ~50-
fold increase as compared to expression of wild-type IDS) that accumulates inside the cells. Co-
localization of edited-to-wild-type R8X- or P4Sfs-IDS with LAMP-1 was low (approximately 10%). 
We analyzed also the co-localization of mutant IDS with the Golgi marker giantin or the early 
endosome marker EEA1, and the results demonstrated that edited-mutant IDS did not accumulate in 
the Golgi nor in early endosomes (Figure 7C-D).  
Review of available literature and bioinformatics analysis. 
To ascertain whether there might be other human IDS target sites for RNA editing in addition to those 
investigated here, we comprehensively screened the relevant literature: a computational study that 
aimed to determine the extent of RNA editing in the human transcriptome identified a single U-to-A 
editing site in an intronic position of the unspliced IDS mRNA (chrX 1,48E+08) [Kleinman et al., 
2012]. We also surveyed bioinformatics software resources available online. The RADAR database 
[http://rnaedit.com/] lists three RNA A-to-I editing events affecting 3 distinct sites in the IDS gene, 2 Field Code Changed
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intronic (chrX 1,48567508E+08 and  1,48567509E+08) and 1 exonic  (chrX 1,48577934E+08). We 
also queried the DARNED database [http://darned.ucc.ie/] but no IDS editing sites were found.  
 
DISCUSSION 
The twin aims of this work were (i) to elucidate further the biochemical features of the IDS proteins 
encoded by the mutant mRNAs (p.P4SfsX43 and p.R8X) edited-to-wild-type, which we previously 
observed in three patients affected by Hunter syndrome and (ii) to recapitulate in vitro the site-specific 
editing of RNA, viz. the U–to-C conversion and U deletion [Lualdi et al., 2010].  
The biochemical analysis panel, including the western blotting of proteins in native-PAGE, reducing 
SDS-PAGE and two-dimensional gel electrophoresis of immunoprecipitated proteins, confirmed the 
presence, in the patient’s cell line harbouring p.R8X, of wild-type IDS protein with similar amount, 
molecular weight and charge properties to those noted in the control. In the patient’s cell line 
harbouring p.P4Sfs, the wild-type IDS protein exhibited similar molecular weight and charge 
properties to that of the control, but a comparatively low amount of protein compared to the control.  
Therefore, the wild-type protein detected could only have been translated from the edited IDS 
transcripts identified ex vivo in the two Hunter syndrome patients. The in vitro expression system, 
developed to investigate these observations further, employed different human cell lines and 
successfully recapitulated the site-specific editing of mutated RNA.  
Intriguingly, in cellula, plasmid constructs harbouring both p.R8X and p.P4SfsX43 yielded both 
mutated and edited transcripts, not only when they were transfected into fibroblasts cultured from the 
same Hunter syndrome patients (which were known to be positive for the RNA editing phenomenon) 
but also when they were transfected into healthy donors’ fibroblasts and commercially available HeLa 
and HEK293 cell lines (Table 1).  Whether editing occurs or not therefore appears to be an inherent 
property of the target sequence. However, the observed extent of the nucleotide-correction may 
depend upon the type of transfected cells but may also be regulated by RNA secondary structure and 
the temporal expression of RNA editing enzymes in the same cell population, as described for known 
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editing mechanisms, such as that occurring in APOB [Hwang et al., 2016]. Taken together, these 
results demonstrated that our in vitro system was able to recapitulate the putative correction 
mechanism and that this mechanism, acting independently of cell type, was likely to be dependent 
upon intrinsic characteristics of the editing sites.  
In addition, at the protein level, confocal microscopy yielded evidence both for IDS-GFP expression 
and IDS-GFP lysosomal localization, albeit only partial, in HEK293 cells transfected with the 
pAcGFP1-N vector carrying IDS(p.R8X) (Figures 4B). Similar findings were obtained by flow 
cytometry and imaging flow cytometry analyses (Figures 5 and 6). Based on these results, it is clear 
that our in vitro system was able to recapitulate the observed mechanism ex vivo, leading to partial 
restoration of a certain amount of wild-type IDS RNA and protein which appeared to have, at least to 
some extent, an appropriate lysosomal localization; somewhat unexpectedly, this occurred 
irrespective of the cell type employed.  
To further investigate the finding of a partial lysosomal localization, we extended the analysis to other 
prominent cellular bodies in the patients’ fibroblasts using the confocal high-content screening 
system, which enables automatic high-content imaging and analysis of thousands of individual cells 
visualized by high resolution microscopy. The screening performed on lysosomes, the Golgi 
apparatus and early-endosomes confirmed adequate, although somewhat low, lysosomal localization 
(approximately 10%) of the proteins encoded by the mutant mRNAs (p.P4SfsX43 and p.R8X) edited-
to-wild-type and clearly demonstrated that they did not accumulate in the Golgi nor in the early 
endosomes of the two patients’ cell lines (Figure 7 C-D). 
 Overall, these results concurred with those we previously reported in the Hunter syndrome patient 
samples [Lualdi et al., 2010], but they still did not provide any obvious explanation for the deficiency 
of IDS enzymatic activity in our patient samples. The observed low residual enzymatic activity could 
in principle be explicable in terms of the preferential lysosomal degradation of the ‘corrected’ proteins 
as demonstrated in a recent study of RNA editing in mammalian brain cells [Behm and Öhman, 2016]. 
Formatted: Normal, Tab stops: Not at  0.29" +  0.39"
21 
 
The only other report of an editing-like variant-correction mechanism occurring in the context of a 
human disease gene has been that tentatively noted in the context of GNPTG [Velho et al., 2016]. A 
homozygous c.[328G>T] transversion predicting a p.[Glu110Term] substitution was detected in 
siblings affected by another lysosomal disorder, mucolipidosis III gamma, but this variant was 
undetectable at the cDNA level (only the wild-type GNPTG sequence was evident). Although this 
additional example of ‘enigmatic transcript correction’ remains to be confirmed by in-depth analysis, 
we find it intriguing that it is also associated with a lysosomal disorder, particularly in the light of our 
above suggestion of the preferential lysosomal degradation of the ‘corrected’ proteins. 
The possible instructive role of the nucleotide sequence environment around the mRNA editing sites 
remains to be clarified. Our findings demonstrate that the ex vivo repair mechanism occurring in all 
cell types tested is likely to be critically dependent upon the intrinsic characteristics of the primary 
sequence/secondary structure of the mRNA editing sites themselves. Some proteins involved in the 
response to DNA damage may function in RNA metabolism [Kai, 2016]; conversely, RNA processing 
proteins or protein complexes may be involved in the DNA damage response or may even exhibit 
DNA repair activity themselves [Jobert and Nilsen, 2014]. RNA processing enzymes are known to 
play a role in the maintenance of genomic integrity and in the integration and interconnection of DNA 
and RNA processing pathways in the eukaryotic nucleus. Currently available data point to an 
emerging role for specific Base Excision Repair (BER) proteins in RNA metabolism and RNA 
surveillance pathways [Jobert and Nilsen, 2014]. The unique ability of BER DNA glycosylases to 
recognize even subtle chemical modifications of nucleic acid bases may serve to distinguish normal 
and aberrant RNA molecules [Jobert and Nilsen, 2014]. We may therefore speculate that proteins 
involved in the signaling and repair of DNA damage might also function as part of a novel mRNA 
correction system. Such a system could in principle be recruited to the task of experimentally 
correcting inherited gene lesions at the RNA level, thereby opening up new therapeutic avenues for 
the future.  
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We conclude that despite the editing of the mutant IDS mRNA molecules to wild-type, and despite 
these mRNAs being translated, the fate of the protein products of translation of these mRNAs is 
qualitatively and quantitatively different from that expected of normal wild-type IDS. We rationalize 
the situation as follows: firstly, the IDS mRNA transcripts harbouring the nonsense/frameshift 
mutations have managed to elude nonsense-mediated mRNA decay. Secondly, a sizeable proportion 
of the mutant IDS mRNA transcripts have been edited to wild-type. Thirdly, despite the correction of 
the IDS mRNA sequence by editing so that they can be properly translated, the cell still appears to 
treat 'corrected' IDS protein translated from these mRNAs differently from IDS protein translated 
from wild-type IDS mRNAs in normal individuals. Thus, the success of the mRNA editing correction 
process notwithstanding, it may well be that these essentially wild-type IDS mRNAs have already 
been tagged by the cell as ‘abnormal’ and hence all subsequent translation products have, at an early 
stage, been earmarked for destruction despite the evident translatability of the edited IDS mRNAs 
[Inada, 2017]. 
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FIGURE LEGENDS  
Figure 1. Representative western blots on lymphoblasts from Hunter syndrome patients 
(p.P4Sfs and p.R8X) and controls (WT). IDS protein detection under SDS-reducing (A) and native 
(B) conditions. The western blots, obtained using an anti-IDS antibody, exhibited a major band in 
samples from both controls and patients, which exhibited identical electrophoretic migration 
properties to that of the IDS protein reference noted in SDS-PAGE. (C) Bar plot of IDS protein 
expression levels. The values from the densitometric analysis are expressed as optical density (OD) 
and revealed a decrease in IDS protein expression between the control and the patient harboring 
p.P4Sfs. The values quoted represent the means of triplicate measurements. Error bars represent 
standard deviations. Anti-tubulin was used as a housekeeping control.   
Figure 2. Representative two-dimensional gel electrophoresis of immunoprecipitation from 
Hunter syndrome patients (p.P4Sfs and p.R8X) and controls (WT). Representative silver staining 
of the anti-IDS immunoprecipitation revealing three spots (circled) corresponding to the molecular 
weight of IDS protein. These three spots exhibited optical density changes comparable to those noted 
in the western blot experiments; however, no difference in either molecular weight or isoelectric point 
was evident between the control and the patient harboring p.R8X.  It should be noted that the p.P4Sfs 
sample is not visible, probably due to its low expression (also observed by western blotting). 
Figure 3. Capillary electrophoretic patterns obtained from transfection of expression vectors. 
The expression vectors contained (P4Sfs)-, (R8X)- and (W12X)-IDS cDNA (A, B and C, 
respectively) into patient fibroblasts (a,b), normal control fibroblasts (c) and the HEK293 (d) and 
HeLa (e) cell lines. Detection primers were designed so that their 3’ ends corresponded to the 
nucleotides (nt) closest to the uracils (thymines) to be corrected; that is at the –1 position (forward 
primer) for the single base deletion, and at the +2 position (reverse primer) for the base conversion 
[Lualdi et al, 2010]. Either ddCTP (base deletion, black peak) or ddGTP (base conversion, blue peak) 
would be incorporated when the mutant IDS mRNAs were corrected, whereas ddTTP and ddATP 
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would be added if the mutant IDS mRNAs remained uncorrected. In the case of base deletion, the 
black peak would denote the normal nt C, whilst the red peak would denote the inserted (unedited) nt 
T (Figure 3A). In the case of base conversion (detection primer being the reverse), the blue peak 
would denote the normal (edited) nt G (C), whereas the green peak would denote the mutated 
(unedited) nt A (T) (Figure 3B). In addition, in the case of G>A conversion (W12X), using a reverse 
primer, only ddATP (red peak) was added as the mutant IDS mRNA remained uncorrected (Figure 
3C).   
Figure 4. IDS-GFP protein expression in HEK293 cells and co-localization with lysosomes 
visualised by confocal microscopy.  HEK293 cells, transiently transfected with wild-type (A) or 
mutated (B and C) IDS-GFP (green fluorescence), were loaded with Hoechst 33342 dye (blue 
fluorescence) to stain the nucleus and incubated with LysoTracker (red fluorescence) to stain the 
lysosomes. The cells were immediately analysed by confocal microscopy as described in the 
Materials and Methods. The cells transfected with either IDS(WT)-GFP or with IDS(R8X)-GFP 
expressed a high level of chimeric protein, whereas the cells transfected with IDS(W12X)-GFP 
displayed almost no GFP signal (second column, A, B and C, respectively). In the third column, a 
cytoplasmic distribution which left the nucleus free of staining was demonstrated by LysoTracker 
staining (red). The fourth column (Merge) displays the distribution of IDS-GFP (green) in cells 
labeled with LysoTracker (red) showing localization within lysosomes (yellow-orange): confocal 
images showed significant overlap (yellow-orange) for IDS(WT)-GFP(A) and IDS(R8X)-GFP (B) 
but no overlap for IDS(W12X) (C). Colocalization with LysoTracker is particularly clear in cells 
expressing low levels of IDS-GFP (arrowheads), as in the inset with higher magnification in (B). In 
the fifth column, differential interference contrast (DIC) images show the number and morphology 
of the cells expressing IDS(WT), IDS(R8X) and IDS(W12X). 
Figure 5: Flow cytometric analysis of GFP expression. (A) Dot plot of HEK293 Side Scatter (SSC) 
peak width against SSC peak height set to gate on single cells and to exclude aggregates. (B) Single 
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cell population analyzed for GFP level of expression. Considered a slight auto-fluorescence of 
cultured cells in the first emission channel (FL1), the negative is set on CTRL (not expressing GFP) 
auto-fluorescence. HEK 293 cells harbouring IDS(R8X) display a level of GFP expression (green 
spots on the right) that almost overlaps with the IDS(WT) sample (57% and 54%, respectively). In 
HEK293 cells harbouring IDS(W12X), the GFP expression is strongly reduced (16%) whilst the mean 
fluorescence intensity (MFI) is distinctly lower. 
Figure 6. Image flow cytometric co-localization analysis. (A) The histogram values derive from a 
feature (Gradient RMS) that measures and plots the sharpness of an image, thereby determining its 
overall focus quality. In-focus cells are gated and then (B) analyzed on the basis of two physical 
qualities: Aspect ratio and Area of the brightfield. Aspect ratio was calculated based on brightfield as 
the ratio of cellular minor axis (width) to major axis (height). Round cells have an aspect ratio close 
to 0.8-1, whereas the elongated cells or clumps have a lower aspect ratio. We gated on round single 
cells of the correct dimension (Area) for further analysis (gate “HEK293”). (C) HEK293 cells were 
visualized on a dot plot based on their expression of GFP and LysoTracker. (D) To improve the visual 
observations and identify the best images, a statistical analysis of double positive events similarity in 
the staining patterns was performed. The bright detail similarity values were calculated using an 
algorithm for co-localization based upon the relative intensities in individual pixels of a cell. Since 
each pixel has a spatial registry, pixel intensity values in different channels can be compared. 
IDS(WT) (E) and IDS(R8X) (F) co-localization are shown (yellow-orange in Ch02/Ch05). 
Figure 7. Representative images obtained from confocal high-content analysis of cells 
expressing wild-type or mutated IDS. IDS protein (red) immunolocalization in fibroblasts from 
control individuals (wt-IDS) and from Hunter syndrome patients (P4Sfs-, R8X- and W12X-IDS). (A) 
Wild-type IDS protein is expressed in fibroblasts from a healthy individual and co-localizes with 
LAMP-1, a lysosome marker (green). (B) In fibroblasts from Hunter syndrome patients bearing the 
p.W12X mutation, mutant IDS is expressed at a very low level, and does not co-localize with LAMP-
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1. Fibroblasts from Hunter syndrome patients bearing either the p.R8X (C) or the p.P4Sfs (D) 
mutations exhibit very high levels of expression of the edited mutant protein, which partially co-
localizes with LAMP-1 (lysosome). However, no co-localization is evident with the Golgi marker, 
giantin (yellow) or the early endosome marker, EEA1 (yellow). Bar = 10 µm. 
